-
1.发明授权公开(公告)号：US07754213B2
公开(公告)日：2010-07-13
申请号：US11875017
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
公开(公告)号：US20090130093A1
公开(公告)日：2009-05-21
申请号：US12294616
申请日：2007-03-27
申请人： Emma Suzanne Cohen , Ralph Raymond Minter , Paula Rosamund Harrison , Matthew Alexander Sleeman , Andrew Donald Nash , Louis Jerry Fabri
发明人： Emma Suzanne Cohen , Ralph Raymond Minter , Paula Rosamund Harrison , Matthew Alexander Sleeman , Andrew Donald Nash , Louis Jerry Fabri
CPC分类号： C07K16/2866 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76
摘要： Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.
摘要翻译： 粒细胞巨噬细胞集落刺激因子（GM-CSFRalpha）受体α链的结合成员，特别是抗体分子。 使用结合成员治疗炎性和自身免疫疾病，例如， 类风湿关节炎，哮喘，过敏反应，多发性硬化，骨髓性白血病和动脉粥样硬化。
-
公开(公告)号：US08613925B2
公开(公告)日：2013-12-24
申请号：US12445753
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.
摘要翻译： 本文公开了通过受体细胞外区域的结构域3结合hIL-13Rα1和IL-13受体介导的信号传导的人白细胞介素-13受体α1的抗体拮抗剂。 这些抗体尤其用于治疗或预防IL-13相关疾病和疾病。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗hIL-13Rα1介导的活性的方法。
-
4.发明授权Method of treating pulmonary disease by administering an antibody to G-CSF receptor 有权通过给予G-CSF受体的抗体来治疗肺部疾病的方法公开(公告)号：US08574572B2
公开(公告)日：2013-11-05
申请号：US12377256
申请日：2007-08-10
IPC分类号： A61K39/395
CPC分类号： C12N15/1138 , A01K67/027 , A01K2227/105 , A01K2267/0368 , A61K38/1793 , A61K39/3955 , A61K45/06 , A61K48/00 , A61K2039/505 , C07K14/535 , C07K16/22 , C07K16/243 , C07K16/2863 , C07K2317/73 , C12N15/1136
摘要： The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.
摘要翻译： 本发明一般涉及用于治疗或预防或以其他方式改善特征为嗜中性粒细胞浸润或与之相关的肺部疾病的影响的方法及其引起的并发症。 本发明还提供包含抑制G-CSF或其受体的活性，干扰G-CSF信号传导和/或下调G-CSF或其受体表达的试剂和药物组合物。
-
公开(公告)号：US08263075B2
公开(公告)日：2012-09-11
申请号：US11692008
申请日：2007-03-27
申请人： Emma Suzanne Cohen , Ralph Raymond Minter , Paula Rosamund Harrison , Matthew Alexander Sleeman , Andrew Donald Nash , Louis Jerry Fabri
发明人： Emma Suzanne Cohen , Ralph Raymond Minter , Paula Rosamund Harrison , Matthew Alexander Sleeman , Andrew Donald Nash , Louis Jerry Fabri
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00
CPC分类号： C07K16/2866 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76
摘要： Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.
摘要翻译： 为粒细胞巨噬细胞集落刺激因子（GM-CSFRα），特别是抗体分子的α链受体提供了结合成员。 使用结合成员治疗炎性和自身免疫疾病，例如， 还提供类风湿性关节炎，哮喘，过敏反应，多发性硬化，骨髓性白血病和动脉粥样硬化。
-
6.发明申请MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RALPHA1) 有权白细胞介素-1受体ALPHA 1（IL-13RALPHA1）的单克隆抗体公开(公告)号：US20110020363A1
公开(公告)日：2011-01-27
申请号：US12828589
申请日：2010-07-01
申请人： Felicity Meredith DUNLOP , Manuel BACA , Andrew Donald NASH , Louis Jerry FABRI , Douglas James HILTON , Nicos A. NICOLA
发明人： Felicity Meredith DUNLOP , Manuel BACA , Andrew Donald NASH , Louis Jerry FABRI , Douglas James HILTON , Nicos A. NICOLA
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/55 , C07K2319/00
摘要： The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.
摘要翻译： 本发明一般涉及结合白细胞介素-13受体α1链（IL-13Rα1）并通过IL-13和/或IL-4拮抗IL-13受体介导的信号传导的抗体。 更具体地说，本发明为哺乳动物，特别是IL-13R.α提供人源化或人抗体。 这些抗体在治疗或预防IL-13和/或IL-4介导的疾病或病症中具有应用。 本发明进一步考虑通过施用受试者抗体调节IL-13和/或IL-4介导的疾病或病症的方法。 本发明还提供了可用于鉴定通过IL-13受体复合物调节IL-13和/或IL-4信号传导的抗体或其它试剂的测定系统。 因此，还提供了筛选IL-13R.alpha.1 /配体相互作用的调节剂的方法。
-
7.发明申请公开(公告)号：US20100285035A1
公开(公告)日：2010-11-11
申请号：US12774966
申请日：2010-05-06
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , A61P35/00 , A61P1/00 , A61P17/06 , A61P11/06 , A61P37/08 , A61P29/00 , A61P17/00 , C12N15/60 , C12N5/10
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
8.发明申请公开(公告)号：US20080166343A1
公开(公告)日：2008-07-10
申请号：US11875017
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
公开(公告)号：US09193793B2
公开(公告)日：2015-11-24
申请号：US13495539
申请日：2012-06-13
申请人： Andrew Donald Nash , Arna Elizabeth Andrews , Manuel Baca , Kirsten Mae Edwards , Matthew Philip Hardy , Con Panousis , Felicity Meredith Dunlop
发明人： Andrew Donald Nash , Arna Elizabeth Andrews , Manuel Baca , Kirsten Mae Edwards , Matthew Philip Hardy , Con Panousis , Felicity Meredith Dunlop
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
摘要翻译： 本公开提供了包含结合人粒细胞集落刺激因子受体的抗体的抗原结合结构域的蛋白质。
-
10.发明授权公开(公告)号：US08568722B2
公开(公告)日：2013-10-29
申请号：US12774966
申请日：2010-05-06
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.027 秒)
